July 11, 2017 CoG for Life http://www.fiercepharma.com/vaccines/eager-for-marketing-approval-gsk-s-shingrix-passes-revaccination-test With GlaxoSmithKline eager for marketing approval, Shingrix passes revaccination test Awaiting a potential FDA approval, GlaxoSmithKline’s much-anticipated shingles vaccine Shingrix met its goal in a phase 3 study examining whether it can protect older adults who have previously received Merck’s Zostavax. If approved, CDC officials said they’re likely to recommend the GSK vaccine over Merck’s shot. In the revaccination study, investigators found that Glaxo’s shot induces a strong immune response in people 50 and older who received Zostavax a minimum of 5 years before their Shingrix vaccination. Since previous studies have shown Zostavax’s...
